Holland D - Search Results

1

Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Belknap R, et al. Among authors: holland d. Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7. Ann Intern Med. 2017. PMID: 29114781 Free PMC article. Clinical Trial.

2

Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements.

Johnson MG, Stout JE, Benator DA, Whitworth WC, Holland DP. Johnson MG, et al. Among authors: holland dp. Int J Tuberc Lung Dis. 2016 May;20(5):600-4. doi: 10.5588/ijtld.15.0570. Int J Tuberc Lung Dis. 2016. PMID: 27084812 Free PMC article.

3

Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.

Holland DP, Hamilton CD, Stout JE. Holland DP, et al. Int J Tuberc Lung Dis. 2016 Jun;20(6):827-31. doi: 10.5588/ijtld.15.0006. Int J Tuberc Lung Dis. 2016. PMID: 27155188 Free PMC article. Clinical Trial.

4

Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Shepardson D, et al. Among authors: holland dp. Int J Tuberc Lung Dis. 2013 Dec;17(12):1531-7. doi: 10.5588/ijtld.13.0423. Int J Tuberc Lung Dis. 2013. PMID: 24200264 Free PMC article.

5

Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.

Holland DP, Sanders GD, Hamilton CD, Stout JE. Holland DP, et al. Am J Respir Crit Care Med. 2009 Jun 1;179(11):1055-60. doi: 10.1164/rccm.200901-0153OC. Epub 2009 Mar 19. Am J Respir Crit Care Med. 2009. PMID: 19299495 Free PMC article.

6

Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.

Holland DP, Sanders GD, Hamilton CD, Stout JE. Holland DP, et al. PLoS One. 2011;6(7):e22276. doi: 10.1371/journal.pone.0022276. Epub 2011 Jul 18. PLoS One. 2011. PMID: 21789248 Free PMC article.

7

Treating latent tuberculosis with rifampin: is it the cheaper option?

Stout JE, Holland DP. Stout JE, et al. Thorax. 2010 Jul;65(7):572-3. doi: 10.1136/thx.2010.138685. Thorax. 2010. PMID: 20627909 No abstract available.

8

Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.

Holland DP, Sanders GD, Hamilton CD, Stout JE. Holland DP, et al. PLoS One. 2012;7(1):e30194. doi: 10.1371/journal.pone.0030194. Epub 2012 Jan 17. PLoS One. 2012. PMID: 22272302 Free PMC article.

9

Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.

Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE. Holland DP, et al. Pharmacotherapy. 2009 May;29(5):503-10. doi: 10.1592/phco.29.5.503. Pharmacotherapy. 2009. PMID: 19397460

10

Translating tuberculosis research into practice: collaboration between academic researchers and public health departments in North Carolina.

Holland DP, Hecker EJ, Mosher AW, Stout JE. Holland DP, et al. N C Med J. 2013 Sep-Oct;74(5):449-54. N C Med J. 2013. PMID: 24165780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,030 results

Search Page